to the FDA upon the completion of planned and ongoing studies.

(f) Two “approvable” letters were received by Wyeth in April and December 2007 from the FDA for Viviant (bazedoxifene), for the prevention of post-menopausal osteoporosis, that set forth the additional requirements for approval. In May 2008, Wyeth received an “approvable” letter from the FDA for the treatment of post- menopausal osteoporosis. The FDA is seeking additional data, and we have been systematically working through these requirements and seeking to address the FDA's concerns. A full response will be provided to the FDA. In February 2008, the FDA advised Wyeth that it expects to convene an advisory committee to review the pending NDAs for both the treatment and prevention indications after we submit our response to the “approvable” letters. In April 2009, Wyeth received approval in the EU for CONBRIZA (the EU trade name for Viviant) for the treatment of post-menopausal osteoporosis in women at increased risk of fracture. Viviant was also approved in Japan in July 2010 for the treatment of post-menopausal osteoporosis and in South Korea in November 2011 for the treatment and prevention of post-menopausal osteoporosis.

  PRODUCT

Eliquis (Apixaban)(a)

Toviaz

Eliquis (Apixaban)(a)

Inlyta (Axitinib) Sutent

Bazedoxifene-conjugated estrogens

Prevenar 13 Infant

Lyrica (Pregabalin) Inlyta (Axitinib)

Xalkori (Crizotinib)

Lyrica (Pregabalin)

Tofacitinib Tofacitinib

Bosutinib(b)

DESCRIPTION OF EVENT

Approval in Japan for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Approval in Japan for treatment of overactive bladder

Approval in the EU for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Approval in the EU for treatment of advanced renal cell carcinoma after failure of prior systemic treatment

Approval in Japan for treatment of pancreatic neuroendocrine tumor

Application filed in the EU for treatment of symptoms associated with menopause and osteoporosis

Application filed in Japan for prevention of invasive pneumococcal disease in infants and young children

Approval in Japan for treatment of fibromyalgia

Approval in Japan for treatment of renal cell carcinoma not indicated for curative resection, metastatic renal cell carcinoma

Approval in Japan for treatment of ALK-positive advanced non- small cell lung cancer

Application filed in Japan for treatment of neuropathic pain: peripheral neuropathic pain, central neuropathic pain

Application filed in Japan for treatment of rheumatoid arthritis

Application filed in the EU for treatment of moderate-to-severe active rheumatoid arthritis

Application filed in the EU for treatment of previously treated chronic myelogenous leukemia

REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN

         Xalkori (Crizotinib) Conditional marketing authorization in the EU for treatment of October 2012 — previously treated ALK-positive advanced non-small cell lung cancer

* For applications in the EU, the dates set forth in this column are the dates on which the European Medicines Agency (EMA) validated our submissions.

(a) This